The FDA’s Trust Problem: Big Pharma Money, Revolving Doors, and Public Outrage
The U.S. Food and Drug Administration (FDA), once considered the trusted guardian of public health, is facing growing scrutiny and a serious credibility crisis. Many Americans are increasingly convinced that the agency, originally tasked with regulating Big Pharma, is instead entangled with it—undermining its ability to serve the public.
From funding by the pharmaceutical industry to a revolving door of former FDA officials taking high-paying jobs at drug companies, the agency’s image has shifted from watchdog to lapdog. Scandals like the opioid crisis and the controversial approval of the Alzheimer’s drug Aduhelm have only fueled public outrage, leading to a deeper trust deficit.
1. Big Pharma Funds the FDA—Literally
While the FDA is often seen as a government entity, its funding model tells a different story. The Prescription Drug User Fee Act (PDUFA), passed in 1992, allows the pharmaceutical industry to pay the FDA directly for reviewing new drug applications. By 2022, these “user fees” accounted for more than 75% of the budget for the agency’s drug approval center.
Critics argue this financial dependence on Big Pharma compromises the FDA’s ability to remain unbiased. Dr. Michael Carome of Public Citizen warned,
> “You can’t serve two masters.”
2. The Revolving Door Is Real—and Spinning Fast
The close ties between the FDA and the pharmaceutical industry extend beyond financial matters. Former FDA officials often leave the agency to take lucrative positions at the companies they once regulated.
Examples include:
- Dr. Scott Gottlieb, former FDA commissioner, joining the Pfizer board of directors shortly after leaving the agency in 2019.
- Dr. Stephen Hahn, another former commissioner, now works with Flagship Pioneering, a venture capital firm that funds biotech companies needing FDA approval.
- Daniel Troy, the FDA’s former top lawyer, moved on to become general counsel at GlaxoSmithKline.
This revolving door raises serious concerns about regulatory integrity and impartiality.
3. The Opioid Crisis: A Case Study in Regulatory Failure
Perhaps no issue has eroded public trust in the FDA more than the opioid epidemic. The FDA’s approval of OxyContin in the late 1990s is a prime example of the agency’s failure to protect public health. Despite clear evidence that OxyContin posed significant addiction risks, Purdue Pharma minimized these dangers, and the FDA approved the drug anyway.
Worse still, Curtis Wright, the FDA official who oversaw OxyContin’s approval, went on to work for Purdue Pharma after his tenure. He reportedly played a role in crafting the misleading drug label that contributed to the nationwide opioid crisis, which has claimed more than 500,000 lives.
4. Shady Approvals: The Case of Aduhelm
The approval of Aduhelm, a controversial Alzheimer’s drug from Biogen, raised further questions about the FDA’s regulatory practices. In 2021, despite strong opposition from its advisory panel, the FDA approved the drug based on questionable data about its effectiveness.
An investigation by The New York Times revealed secret meetings between FDA officials and Biogen executives before the approval. Ten out of eleven FDA advisers voted against the drug’s approval. Yet, it still received the green light.
Such actions have led many to believe that the FDA’s decision-making process is not driven by science, but by industry influence.
5. Can the FDA Regain Public Trust?
There are potential solutions to restore confidence in the FDA. Proposals include:
- Banning officials from working in the pharmaceutical industry for several years after leaving the agency.
- Making all drug trial data public and independently verifiable.
- Overhauling the FDA’s funding model to reduce its reliance on industry fees.
However, until these changes are made, skepticism about the FDA is likely to persist.
As Dr. Diana Zuckerman of the National Center for Health Research aptly stated,
> “The public’s trust is hard-earned and easily lost. It’s time to restore the FDA to what it was meant to be—a watchdog, not a lapdog.”
---
Sources & References:
1. FDA Budget Reports (https://www.fda.gov)
2. Public Citizen – FDA and Big Pharma (https://www.citizen.org)
3. Scott Gottlieb Joins Pfizer (https://www.reuters.com)
4. ProPublica on the Opioid Epidemic (https://www.propublica.org)
5. NYT on Aduhelm Approval (https://www.nytimes.com)
6. GAO Report on FDA Conflicts (https://www.gao.gov)
7. The OxyContin Files – Washington Post (https://www.washingtonpost.com)
8. FDA Revolving Door Tracker – POGO (https://www.pogo.org)
The U.S. Food and Drug Administration (FDA), once considered the trusted guardian of public health, is facing growing scrutiny and a serious credibility crisis. Many Americans are increasingly convinced that the agency, originally tasked with regulating Big Pharma, is instead entangled with it—undermining its ability to serve the public.
From funding by the pharmaceutical industry to a revolving door of former FDA officials taking high-paying jobs at drug companies, the agency’s image has shifted from watchdog to lapdog. Scandals like the opioid crisis and the controversial approval of the Alzheimer’s drug Aduhelm have only fueled public outrage, leading to a deeper trust deficit.
1. Big Pharma Funds the FDA—Literally
While the FDA is often seen as a government entity, its funding model tells a different story. The Prescription Drug User Fee Act (PDUFA), passed in 1992, allows the pharmaceutical industry to pay the FDA directly for reviewing new drug applications. By 2022, these “user fees” accounted for more than 75% of the budget for the agency’s drug approval center.
Critics argue this financial dependence on Big Pharma compromises the FDA’s ability to remain unbiased. Dr. Michael Carome of Public Citizen warned,
> “You can’t serve two masters.”
2. The Revolving Door Is Real—and Spinning Fast
The close ties between the FDA and the pharmaceutical industry extend beyond financial matters. Former FDA officials often leave the agency to take lucrative positions at the companies they once regulated.
Examples include:
- Dr. Scott Gottlieb, former FDA commissioner, joining the Pfizer board of directors shortly after leaving the agency in 2019.
- Dr. Stephen Hahn, another former commissioner, now works with Flagship Pioneering, a venture capital firm that funds biotech companies needing FDA approval.
- Daniel Troy, the FDA’s former top lawyer, moved on to become general counsel at GlaxoSmithKline.
This revolving door raises serious concerns about regulatory integrity and impartiality.
3. The Opioid Crisis: A Case Study in Regulatory Failure
Perhaps no issue has eroded public trust in the FDA more than the opioid epidemic. The FDA’s approval of OxyContin in the late 1990s is a prime example of the agency’s failure to protect public health. Despite clear evidence that OxyContin posed significant addiction risks, Purdue Pharma minimized these dangers, and the FDA approved the drug anyway.
Worse still, Curtis Wright, the FDA official who oversaw OxyContin’s approval, went on to work for Purdue Pharma after his tenure. He reportedly played a role in crafting the misleading drug label that contributed to the nationwide opioid crisis, which has claimed more than 500,000 lives.
4. Shady Approvals: The Case of Aduhelm
The approval of Aduhelm, a controversial Alzheimer’s drug from Biogen, raised further questions about the FDA’s regulatory practices. In 2021, despite strong opposition from its advisory panel, the FDA approved the drug based on questionable data about its effectiveness.
An investigation by The New York Times revealed secret meetings between FDA officials and Biogen executives before the approval. Ten out of eleven FDA advisers voted against the drug’s approval. Yet, it still received the green light.
Such actions have led many to believe that the FDA’s decision-making process is not driven by science, but by industry influence.
5. Can the FDA Regain Public Trust?
There are potential solutions to restore confidence in the FDA. Proposals include:
- Banning officials from working in the pharmaceutical industry for several years after leaving the agency.
- Making all drug trial data public and independently verifiable.
- Overhauling the FDA’s funding model to reduce its reliance on industry fees.
However, until these changes are made, skepticism about the FDA is likely to persist.
As Dr. Diana Zuckerman of the National Center for Health Research aptly stated,
> “The public’s trust is hard-earned and easily lost. It’s time to restore the FDA to what it was meant to be—a watchdog, not a lapdog.”
---
Sources & References:
1. FDA Budget Reports (https://www.fda.gov)
2. Public Citizen – FDA and Big Pharma (https://www.citizen.org)
3. Scott Gottlieb Joins Pfizer (https://www.reuters.com)
4. ProPublica on the Opioid Epidemic (https://www.propublica.org)
5. NYT on Aduhelm Approval (https://www.nytimes.com)
6. GAO Report on FDA Conflicts (https://www.gao.gov)
7. The OxyContin Files – Washington Post (https://www.washingtonpost.com)
8. FDA Revolving Door Tracker – POGO (https://www.pogo.org)